Research programme: wound healing therapeutics - Compass Biomedical
Latest Information Update: 27 Dec 2016
At a glance
- Originator Arteriocyte
- Class Stem cell therapies
- Mechanism of Action Angiogenesis inducing agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Wounds
Most Recent Events
- 12 Dec 2016 Arteriocyte is now called Compass Biomedical
- 21 Jan 2011 Discontinued for Wounds in USA (unspecified route)